Voleon Capital Management LP Acquires Shares of 671 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Voleon Capital Management LP acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 671 shares of the biopharmaceutical company's stock, valued at approximately $478,000.

Several other institutional investors have also recently added to or reduced their stakes in the company. OFI Invest Asset Management purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $28,000. Rakuten Securities Inc. increased its stake in Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 15 shares during the period. Avalon Trust Co purchased a new stake in Regeneron Pharmaceuticals during the 4th quarter worth approximately $36,000. Crowley Wealth Management Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $36,000. Finally, Private Wealth Management Group LLC grew its position in shares of Regeneron Pharmaceuticals by 260.0% during the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock worth $38,000 after buying an additional 39 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Analyst Upgrades and Downgrades

REGN has been the topic of several analyst reports. Robert W. Baird lowered their target price on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a research report on Friday, April 25th. UBS Group dropped their target price on shares of Regeneron Pharmaceuticals from $768.00 to $633.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 30th. Canaccord Genuity Group raised Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Tuesday, April 22nd. Royal Bank of Canada reduced their target price on shares of Regeneron Pharmaceuticals from $1,051.00 to $943.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 30th. Finally, Bernstein Bank cut their target price on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. One analyst has rated the stock with a sell rating, five have issued a hold rating, eighteen have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $892.60.

Regeneron Pharmaceuticals Trading Down 0.3 %

Regeneron Pharmaceuticals stock traded down $2.03 during trading on Monday, reaching $603.58. 1,124,250 shares of the company were exchanged, compared to its average volume of 746,539. The company has a market capitalization of $65.99 billion, a P/E ratio of 15.77, a PEG ratio of 2.34 and a beta of 0.44. Regeneron Pharmaceuticals, Inc. has a 52-week low of $525.99 and a 52-week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The stock's 50 day simple moving average is $626.49 and its two-hundred day simple moving average is $707.37.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). The firm had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. Regeneron Pharmaceuticals's revenue for the quarter was down 3.7% on a year-over-year basis. During the same period last year, the firm posted $9.55 earnings per share. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.58%. The ex-dividend date is Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is 8.96%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.